期刊文献+

Analysis of CD117-negative gastrointestinal stromal tumors 被引量:14

Analysis of CD117-negative gastrointestinal stromal tumors
下载PDF
导出
摘要 AIM: To identify the gastrointestinal stromal tumors(GISTs) that are negative for CD117 expression by immunohistochemistry and to characterize their malignant potential.METHODS: A total of 108 primary mesenchymal tumors of the gastrointestinal tract were screened to select CD117-negative tumors, from which KIT(exons 9, 11, 13, and 17)and PDGFRA (exons 10, 12, 14, and 18) were sequenced to identify GISTs. Tumor recurrence and distant metastasis were used as the criteria of malignancy.RESULTS: The result showed that approximately 25%(29/108) of the gastrointestinal mesenchymal tumors were negative for CD117 and approximately 6% (7/108)of the tumors were CD117-negative GISTs. All these CD117-negative tumors had a mutated KITand a wildtype PDGFRA. All CD117-negative GISTs with mutations at codons 557/558 of KIThad mitotic counts >10/50 high power field, and 75% (3/4) of them showed multiple recurrence or distant metastasis.CONCLUSION: CD1 17-negative KITmutated GISTs account for approximately 6% of the gastrointestinal mesenchymal tumors. Tumor recurrence or distant metastasis correlates to both theKITmutations at codons 557/558 and the mitotic counts, but not to the tumor size. AIM: To identify the gastrointestinal stromal tumors (GISTs) that are negative for CD117 expression by immunohistochemistry and to characterize their malignant potential. METHODS: A total of 108 primary mesenchymal tumors of the gastrointestinal tract were screened to select CD117-negative tumors, from which KIT(exons 9,11,13, and 17) and PDGFRA (exons 10, 12, 14, and 18) were sequenced to identify GISTs. Tumor recurrence and distant metastasis were used as the criteria of malignancy. RESULTS: The result showed that approximately 25% (29/108) of the gastrointestinal mesenchymal tumors were negative for CD117 and approximately 6% (7/108) of the tumors were CD117-negative GISTs. All these CD117-negative tumors had a mutated KIT and a wildtype PDGFRA. All CD117-negative GISTs with mutations at codons 557/558 of KIT had mitotic counts >10/50 high power field, and 75% (3/4) of them showed multiple recurrence or distant metastasis. CONCLUSION: CD117-negative KITmutated GISTs account for approximately 6% of the gastrointestinal mesenchymal tumors. Tumor recurrence or distant metastasis correlates to both the KIT mutations at codons 557/558 and the mitotic counts, but not to the tumor size.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第7期1052-1055,共4页 世界胃肠病学杂志(英文版)
关键词 CD117 胃肿瘤 肠肿瘤 间叶肿瘤 基因表达 Gastrointestinal stromal tumor CD117 KIT mutation Tumor recurrence Distant metastasis
  • 相关文献

参考文献15

  • 1Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7:507-519.
  • 2Schaldenbrand JD, Appelman HD. Solitary solid stromal gastrointestinal tumors in yon Recklinghausen's disease with minimal smooth muscle differentiation. Hum Pathol 1984;15; 229-232.
  • 3Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-1269.
  • 4Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J,Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP,Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459-465.
  • 5Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33;484-495.
  • 6Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R,Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD,Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61;8118-8121.
  • 7Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R,Nassar A, Sobin LH, Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors.A study of 200 cases. Am J Pathol 2000; 157:1091-1095.
  • 8Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J,Okazaki T, Kitamura Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromaltumours. J Pathol 2001; 193:505-510.
  • 9Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH,O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78. 1633-1636.
  • 10Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of KIT occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.

同被引文献82

引证文献14

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部